As Chronic Myelomonocytic Leukemia (CMML) becomes increasingly prevalent worldwide and contributes to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is a rising need for safer and more effective treatments. DelveInsight reports that more than 20 pharmaceutical and biotech companies are actively developing over 25 therapeutic candidates targeting CMML. These candidates span multiple stages of clinical and preclinical development, reflecting significant innovation and commitment to addressing this critical health challenge.
The “Chronic Myelomonocytic Leukemia Pipeline Insight 2025” report by DelveInsight provides a comprehensive strategic overview of the current R&D landscape. It examines clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives, serving as a vital resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving CMML therapeutics market and the breakthroughs shaping its future.
Explore the Cutting-Edge Landscape of Chronic Myelomonocytic Leukemia Drug Development
Key Takeaways from the Chronic Myelomonocytic Leukemia Pipeline Report
DelveInsight’s Chronic Myelomonocytic Leukemia (CMML) pipeline report highlights a dynamic landscape, with over 20 active companies developing more than 25 therapeutic candidates for CMML treatment.
Key developments in 2025 include:
-
July 2025: The oral therapy Inqovi (venetoclax for acute myeloid leukemia) is under FDA review, with a decision expected by February 25, 2026.
-
July 2025: Taiho Oncology and Taiho Pharmaceutical announced the FDA’s acceptance of a supplemental New Drug Application for INQOVI® in combination with venetoclax to treat patients with acute myeloid leukemia.
Leading companies advancing CMML therapies include ImmuneOnco Biopharma, Immune-Onc Therapeutics, SOLU Therapeutics, CD4CAR, Cobimetinib, BC3402, AZD6738, APG-115, Tuspetinib, NC525, Itacitinib, LP-108, TRX103, PRT2527, DFV890, and others.
Promising pipeline candidates in various stages of development include Timdarpacept, IO-202, STX-0712, among others.
Chronic Myelomonocytic Leukemia Overview:
Chronic myelomonocytic leukemia (CMML) is a rare blood disorder caused by the abnormal clonal expansion of hematopoietic stem cells. It is characterized by elevated monocyte counts and dysplasia (abnormal development) of myeloid precursor cells in the bone marrow. CMML falls under the category of myelodysplastic/myeloproliferative neoplasms (MDS/MPN), a group that also includes atypical CML, juvenile myelomonocytic leukemia, MDS/MPN with ring sideroblasts and thrombocytosis, and other unclassified subtypes.
Download the Chronic Myelomonocytic Leukemia sample report to know in detail about the Chronic Myelomonocytic Leukemia treatment market
Chronic Myelomonocytic Leukemia Pipeline Analysis
The Chronic Myelomonocytic Leukemia pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Chronic Myelomonocytic Leukemia Market.
-
Categorizes Chronic Myelomonocytic Leukemia therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Chronic Myelomonocytic Leukemia drugs under development based on:
-
Stage of development
-
Chronic Myelomonocytic Leukemia Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Chronic Myelomonocytic Leukemia Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Chronic Myelomonocytic Leukemia Licensing agreements
-
Funding and investment activities supporting future Chronic Myelomonocytic Leukemia market advancement.
-
Unlock key insights into emerging Chronic Myelomonocytic Leukemia therapies and market strategies here: https://www.delveinsight.com/report-store/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Chronic Myelomonocytic Leukemia Emerging Drugs
-
Timdarpacept: ImmuneOnco Biopharma
Timdarpacept is an experimental therapy in Phase III development for chronic myelomonocytic leukemia (CMML). It is a recombinant fusion protein that links Signal Regulatory Protein alpha (SIRPα) to an IgG1 backbone, designed to enhance immune system activity against cancer cells.
-
IO-202: Immune-Onc Therapeutics
IO-202 is a novel, humanized IgG1 monoclonal antibody designed to target LILRB4 (Leukocyte Immunoglobulin-Like Receptor Subfamily B4), a receptor that is highly expressed on cells linked to chronic myelomonocytic leukemia (CMML). By binding to LILRB4, IO-202 stimulates the immune system to attack cancer cells through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), promoting the destruction of malignant cells.
Chronic Myelomonocytic Leukemia Pipeline Therapeutic Assessment
Chronic Myelomonocytic Leukemia Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Chronic Myelomonocytic Leukemia By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Chronic Myelomonocytic Leukemia Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Chronic Myelomonocytic Leukemia Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Chronic Myelomonocytic Leukemia therapies and key Chronic Myelomonocytic Leukemia companies
Table of Contents
1. Report Introduction
2. Executive Summary
3. Chronic Myelomonocytic Leukemia Current Treatment Patterns
4. Chronic Myelomonocytic Leukemia – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Chronic Myelomonocytic Leukemia Late-Stage Products (Phase-III)
7. Chronic Myelomonocytic Leukemia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Myelomonocytic Leukemia Discontinued Products
13. Chronic Myelomonocytic Leukemia Product Profiles
14. Chronic Myelomonocytic Leukemia Key Companies
15. Chronic Myelomonocytic Leukemia Key Products
16. Dormant and Discontinued Products
17. Chronic Myelomonocytic Leukemia Unmet Needs
18. Chronic Myelomonocytic Leukemia Future Perspectives
19. Chronic Myelomonocytic Leukemia Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Chronic Myelomonocytic Leukemia pipeline reports offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/